Principal investigator
Sheila Fleming, Ph.D.
Associate Professor of Pharmaceutical Sciences
Director, Neurodegenerative Disease and Aging Research Focus Area
College of Pharmacy
Department of Pharmaceutical Sciences
Sheila Fleming, Ph.D.
Associate Professor of Pharmaceutical Sciences
Director, Neurodegenerative Disease and Aging Research Focus Area
The Fleming lab does research on multiple aspects of Parkinson’s disease that range from identifying molecular mechanisms involved in the interaction of environmental and genetic factors in PD, to testing potential therapeutics (biologics, re-purposed drugs, and exercise therapy) in animal models, to developing a novel protocol for dance therapy for patients. At the core of each of these investigative areas is behavioral function because this is ultimately what we are trying to improve for patients.
The effect of treadmill exercise in the alpha-synuclein preformed fibril rat model of Parkinson’s disease: We find that exercise improves aspects of movement and cognition, and we are now working to extend this project to further investigate the effect of exercise on cognitive and neuropsychiatric function in the alpha-synuclein preformed fibril model of Parkinson’s disease.1R01ES031124
“ATP13A2 and susceptibility to neurodegeneration”
PI: Sheila Fleming, Ph.D.
Agency: NIH/ NIEHS
This grant will investigate how loss of ATP13A2 function affects manganese and alpha-synuclein toxicity in mice.
W81XWH-19-0772
“Exercise effects on synuclein aggregation, neuroinflammation and neurodegeneration”
Initiating PI: Caryl Sortwell, Ph.D.
Partnering PI: Sheila Fleming, Ph.D.
Agency: Department of Defense, Biological mechanisms of impact from exercise on neurodegeneration in Parkinson’s disease
This grant will determine the therapeutic efficacy of exercise in an optimized alpha-synuclein model of Parkinson’s disease.
See any open positions in this lab on the NEOMED careers site.
From Ignite magazine: Showing the progression of Parkinson’s Disease
In a Department of Defense-funded study, researchers in the Fleming Lab investigate the impact of exercise on Parkinson’s pathology and cognitive dysfunction.
Cheri Harris
Business Manager
Phone: 330.325.6689
Email: charris1@380cebbe0d.nxcli.io
Moses Oyewumi, Ph.D.
Phone: 330.325.6669
Email: moyewumi@380cebbe0d.nxcli.io
© 2024 Northeast Ohio Medical University
4209 St. Rt. 44, PO Box 95, Rootstown, Ohio 44272
ADA compliance | Consumer information | Title IX | Privacy statement | Do business with NEOMED